The number of new Covid-19 cases that took place since October 31, 2021, has slowed in the last six months, with a surprising high and limited number being reported by the Centers for Disease Control and Prevention.
According to the CDC, the number of daily new cases in the United States increased from 25,454 on October 31, 2021 to 1.26 million on January 10, only to increase to 9,486 new cases by March 13, and reverse course again, with 88,535 new cases on April 27.
If not for Moderna (MRNA) vaccines and booster shots, the infection rate might be significantly higher, according to the CDC. Reportand Johnson & Johnson (JNJ) - Get Johnson & Johnson Report. According to the Centers for Disease Control and Prevention, 82.5% of people aged 5 to 7 years old and older in the United States have had at least one vaccination injection.
The Food and Drug Administration approved the first emergency use of a Covid-19 vaccine on December 11, 2020, according to the United States Health and Human Services website. Moderna''''s vaccination emergency use for persons 18 and older was approved by the FDA on December 18, 2020. Johnson & Johnson''s Janssen vaccination emergency use for persons 18 and older on February 27, 2021.
The FDA has amended its terms for emergency use of the Pfizer vaccine for children ages 12 to 15, and on October 29, 2021, approved emergency use of the Pfizer vaccine for children ages 5 to 11. However, children under the age of 5 have been denied vaccinations since the outbreak began.
When Will Children Under 5 Get Covid Vaccine?
According to a statement, Moderna became the first drug company to get the FDA''s first vaccine, mRNA-1273, for children aged 6 months old to under two years and 2 years to under six years old.
"We are proud to announce that we have submitted our EUA submission for our COVID-19 vaccination for young children," said Moderna''s CEO. "We believe mRNA-1273 will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19, and will be particularly welcomed by parents and caregivers."
Elon Musk Has an Original Way to Defeat Warren Buffett
A massive Las Vegas Strip project has taken over over a former hotel.
Wendy''s Menu Is Gifted To Taco Bell
The positive interim findings from the Phase 2/3 KidCOVE study highlighted a robust neutralizing antibody response in the 6 month to under 6 years of age group after a two-dose primary series of mRNA-1273, along with a favorable safety profile. The antibody titers in the pre-defined 6 month to 23 month and two years to under 6 years age groups met the study''s primary objective, according to a statement.
The previously reported results included a supportive preliminary efficacy analysis on cases mostly collected during the Omicron wave, including home testing for Covid-19. When the analysis is limited only to cases confirmed positive for SARS-CoV-2 by a central laboratory RT-PCR vaccine, efficacy remained significant at 51% for 6 months to under 2 years and 37% for 2 years to under 6 years. These efficacy estimates are similar to vaccine efficacy estimates in adults against Omicron after two doses of m
Next week, the emergency use authorization submission for children aged 6 months to under 6 years is expected to be completed.
How Safe is the Vaccine for Children?
Dr. Paul Burton, Moderna''s chief medical officer, told CBS News on May 1 that the company will send all of its data electronically to the FDA by May 9 so they may conduct their analysis. However, Burton said that Moderna has already provided the FDA with data they need to begin their study.
Burton was optimistic that the vaccination would be effective for children aged between 6 and 6 years old.
"So, first of all, on safety -- and we can talk about that -- the safety profile we see with this vaccine, in these very very young children, was quite positive. Actual rates of safety events, even lower than we see in the six-year-olds to 12-year-olds. "So that''s great," Burton told "Face the Nation."